A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients

Andrew Dakin, Ray Borrow, Peter D. Arkwright

Research output: Contribution to journalArticlepeer-review


Introduction: Hexaxim is a hexavalent vaccine approved in 2013 for use the EU as primary and booster vaccination in infants 6 weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b.
Areas Covered: To evaluate the immunogenicity and reactogenicity (safety) of Hexaxim (Hexyon, Hexacima) in primary and booster vaccine schedules; long-term antibody persistence; concomitant use with other childhood vaccines and use in immunocompromised infants. Hexaxim was found to be noninferior to other hexavalent vaccines on the market, being highly immunogenic for all toxoids/antigens and with an acceptable safety profile. It can be administered concomitantly with other childhood vaccines and provides long lasting immune protection against all diseases, including hepatitis B. Hexaxim can be given as a booster for infants primed with Infanrix Hexa and can be given in a pentavalent-hexavalent-pentavalent series. Hexaxim elicits a similar immune response and safety profile in Human immunodeficiency virus (HIV) positive infants. It has the benefit of being a ready to use liquid formulation, minimising dosage errors and preparation time.
Expert Opinion: Hexaxim has an acceptable safety profile and provides immunity against all six targeted diseases, including long lasting hepatitis B antibody persistence. It is an acceptable alternative to other hexavalent vaccines on the market. Further studies are required on the use in immunocompromised patients as well as the antibody persistence of each of the vaccine components.
Original languageEnglish
JournalExpert Reviews of Vaccines
Publication statusAccepted/In press - 20 Dec 2022


  • Hexavalent vaccine
  • Hexaxim
  • Hexyon
  • diphtheria
  • tetanus
  • polio
  • Haemophilus
  • hepatitis B


Dive into the research topics of 'A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients'. Together they form a unique fingerprint.

Cite this